Niagen Bioscience Q2 net sales up 37% to $31.1M; raises FY2025 guidance to 22%-27% growth

Niagen Bioscience, Inc.

2025-Q2 EPS reported $0.10 revenue$61,598,000

Net sales $31.1M (+37% YoY); net income $3.6M ($0.05 EPS) vs breakeven in Q2 2024.
Gross margin improved 480 bps to 65.0%; adjusted EBITDA $5.0M, up 221%.
Raises FY2025 revenue growth outlook to 22%-27% (previously 20%-25%).
Secured exclusive worldwide license for Niagen in Parkinson's therapy; NOPARK Phase III trial dosing completed, data expected 2026.
Niagen Plus available in 800+ U.S. wellness clinics (up from 475 in Dec 2024); cash $60.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.